Trial ID 20177 | Maryland Oncology Hematology Trial ID 20177 – Maryland Oncology Hematology

Trial ID 20177

Trial Information - Phase III

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)

Protocol ID: M16-191

Sponsor: AbbVie

Status: STAR Trial

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724

Disease Types

Myelofribrosis

Status

STAR Trial

Sponsor

AbbVie

Quality Care Close to Home


View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology